Acute Myeloid Leukemia (AML) Testing – Overview

Acute Myeloid Leukemia (AML) testing involves a series of laboratory and molecular assessments used to diagnose AML, classify its subtype, monitor treatment response, and guide therapy decisions. Since AML is a rapidly progressing blood cancer, accurate and timely testing is critical for effective management.

1. Purpose of AML Testing

• Confirm Diagnosis

Determine whether abnormal myeloid cells (blasts) are present in bone marrow or blood.

• Determine AML Subtype

Classify AML based on genetic mutations, chromosomal abnormalities, and cell markers.

• Guide Targeted Treatment

Identify molecular markers that influence treatment choice.

• Monitor Disease

Track measurable residual disease (MRD), relapse risk, and treatment effectiveness.

• Predict Prognosis

Certain mutations and cytogenetic profiles are linked to good, intermediate, or poor outcomes.